ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into the front lines to witness international advancements and to witness the progress of China's anti-tumor efforts on the global stage. Professor Huiyan Luo from Sun Yat-sen University Cancer Center presented a crucial oral presentation (Abstract ID: 1026MO) at this conference. In this on-site interview, Professor Huiyan Luo shared insights into the study of the treatment of advanced solid tumors using the dual-target antibody SHR-1701, which targets PD-L1 and TGF-βRII, in combination with the VEGF inhibitor bevacizumab, as well as her thoughts on future directions for the treatment of advanced tumors. This article compiles the relevant content for readers.